Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model.

Wang K, Tarakji K, Zhou Z, Zhang M, Forudi F, Zhou X, Koki AT, Smith ME, Keller BT, Topol EJ, Lincoff AM, Penn MS.

J Cardiovasc Pharmacol. 2005 Jan;45(1):61-7.

PMID:
15613981
2.

Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment.

Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM.

Mol Carcinog. 2003 Oct;38(2):49-58.

PMID:
14502644
3.

Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer.

Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM.

Mol Carcinog. 2003 Sep;38(1):33-9.

PMID:
12949841
4.

Renal effects of selective cyclooxygenase inhibition in experimental liver disease.

López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jiménez W, Arroyo V, Rivera F, Rodés J.

Adv Exp Med Biol. 2003;525:133-6. No abstract available.

PMID:
12751752
5.

Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers.

Koki AT, Khan NK, Woerner BM, Seibert K, Harmon JL, Dannenberg AJ, Soslow RA, Masferrer JL.

Prostaglandins Leukot Essent Fatty Acids. 2002 Jan;66(1):13-8. Review.

PMID:
12051953
6.

Celecoxib: a specific COX-2 inhibitor with anticancer properties.

Koki AT, Masferrer JL.

Cancer Control. 2002 Mar-Apr;9(2 Suppl):28-35. Review.

PMID:
11965228
7.

Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites.

López-Parra M, Clària J, Planagumà A, Titos E, Masferrer JL, Woerner BM, Koki AT, Jiménez W, Altuna R, Arroyo V, Rivera F, Rodés J.

Br J Pharmacol. 2002 Feb;135(4):891-900.

8.

Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.

Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE.

Anticancer Res. 2001 Sep-Oct;21(5):3425-32.

PMID:
11848504
9.

Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo.

Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL.

Cancer Res. 2002 Feb 1;62(3):625-31.

10.

Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon.

Khan KN, Masferrer JL, Woerner BM, Soslow R, Koki AT.

Scand J Gastroenterol. 2001 Aug;36(8):865-9.

PMID:
11495083
11.

Cyclooxygenase-2 is overexpressed in human cervical cancer.

Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL, Subbaramaiah K, Dannenberg AJ.

Clin Cancer Res. 2001 Feb;7(2):429-34.

12.

Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy.

Koki AT, Leahy KM, Masferrer JL.

Expert Opin Investig Drugs. 1999 Oct;8(10):1623-1638.

PMID:
11139815
13.

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT.

Cancer. 2000 Dec 15;89(12):2637-45.

PMID:
11135226
14.

Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats.

Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, Kelloff GJ, Hill DL, Seibert K.

Cancer Res. 2000 Oct 15;60(20):5599-602.

15.

Role of cyclooxygenases in angiogenesis.

Leahy KM, Koki AT, Masferrer JL.

Curr Med Chem. 2000 Nov;7(11):1163-70. Review.

PMID:
11032965
16.

Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors.

Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K.

Cancer Res. 2000 Mar 1;60(5):1306-11.

17.

Visualization and quantitation of cyclooxygenase-1 and -2 activity by digital fluorescence microscopy.

Ornberg RL, Koki AT.

Adv Exp Med Biol. 1999;469:131-7. No abstract available.

PMID:
10667321
18.

Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder.

Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT.

Cancer Res. 1999 Nov 15;59(22):5647-50.

19.

Immunohistochemical analysis of cyclooxygenase expression in human skin.

Buckman SY, Koki AT, Edwards DA, Pentland AP.

Methods Mol Biol. 1999;120:35-43. No abstract available.

PMID:
10343308
20.

Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer.

Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Masferrer JL, Woerner BM, Koki AT, Fahey TJ 3rd.

Cancer Res. 1999 Mar 1;59(5):987-90.

21.

Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck.

Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ.

Cancer Res. 1999 Mar 1;59(5):991-4.

22.

Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflammatory drug-related nephrotoxicity.

Khan KN, Venturini CM, Bunch RT, Brassard JA, Koki AT, Morris DL, Trump BF, Maziasz TJ, Alden CL.

Toxicol Pathol. 1998 Sep-Oct;26(5):612-20.

PMID:
9789947

Supplemental Content

Support Center